Physicians' Academy for Cardiovascular Education
In this e-learning course, the role of novel diabetes treatment approaches in the prevention of CVD in patients with T2DM will be discussed. Member registration (free) is needed to enroll in this course.
Jorge Plutzky describes potential mechanisms for the benefit of some GLP1-RA in CVOTs and discusses their possible effects on atherosclerosis in patients with diabetes.
This 2020 expert consensus decision pathway (ECDP) provides practical guidance on the use of SGLT2i and GLP-1RAs for reducing the risk of CVD in patients with T2DM.
Prof. Marx discusses evidence on how CV risk in diabetes can be reduced by new diabetes agents and current guideline recommendations to manage patients with diabetes and high CV risk.
Recent CVOTs with GLP-1RAs included kidney outcomes as a secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.
ERA-EDTA 2020 An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.
The largest cardiology congress ESC was just announced to turn fully digital. PACE-CME is committed to help sharing the news and deliver our cardiovascular education
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.
This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.
A meta-analysis of GLP-1RA outcome trials show that treatment reduces the risk of CV and kidney events in T2DM. Subgroup analyses did not explain previously observed differences in trial results.
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
